Treatment-related complication rates and mean values of PRU and platelet inhibition among PS and CP groups of patients
| Type of Complicationsa | PS Group (95% CI) | No. of Articles | CP Group (95% CI) | No. of Articles | P Value |
|---|---|---|---|---|---|
| Permanent complications | 6/651 = 1% (1–4) (I2 = 19%) | 6 | 11/617 = 2% (1–4) (I2 = 81%) | 12 | .6 |
| Ischemic/thromboembolic | 16/682 = 2% (1–5) (I2 = 73%) | 7 | 40/672 = 6% (3–13) (I2 = 83%) | 5 | .003b |
| Hemorrhagic | 17/682 = 3% (1–9) (I2 = 73%) | 7 | 16/672 = 3% (1–5) (I2 = 19%) | 5 | .7 |
| Periprocedural complications | 23/682 = 4% (1–11) (I2 = 80%) | 7 | 35/672 = 5% (2–11) (I2 = 82%) | 5 | .7 |
| Delayed complications | 12/682 = 3% (1–6) (I2 = 41%) | 7 | 23/672 = 3% (1–8) (I2 = 71%) | 5 | .8 |
| Treatment-related mortality | 0/682 | 7 | 1/617 = 0.4% (0.1–2) (I2 = 0%) | 4 | .09 |
| Good neurologic outcome | 631/635 = 98% (96–99) (I2 = 5%) | 6 | 606/617 = 97% (97–99) (I2 = 20%) | 4 | .2 |
| Platelet inhibition valuesc | |||||
| Mean resistance rate | 9/433 = 1.8% (0.5–3) (I2 = 0%) | 4 | 99/344 = 30% (23–33) (I2 = 0%) | 2 | .001b |
| Mean PRU | 125.2 (118–132) (I2 = 0%) | 3 | 247.8 (239–256) (I2 = 18%) | 2 | .00b |
| Aneurysm occlusion rate (PS vs CP) | Odds Ratio = 1.21 (95% CI, 0.43–3.39, I2 = 60.2%) | 3 | .723 | ||